Whilst mTOR inhibitors were deemed well tolerated, reduction in seizures in children with FCD did not reach the predefined level of statistical significance in the open-label trials and only one patient underwent genetic testing and had a confirmed mosaic MTOR variant [203]. The gene discussed is MTOR; the disease is fleck corneal dystrophy.